drugset
drugset / Trial / NCT05369858

A Mass Balance and Biotransformation Study of [14C]SKLB1028 in Chinese Healthy Male Subjects

NCT05369858 ↗

Phase 1 Completed 6 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
NaSingle-groupOpen-labelOther

Summary

This is a single-centre, open-label, mass balance and biotransformation study in healthy male subjects utilising a single oral dose of \[14C\] SKLB1028.

Timeline

Start
2021-08-06
Primary completion
2021-09-04
Completion
2021-09-11

Drugs

EvaluationDrugModalityDoseRoute
Subject RUSERONTINIB Small molecule 150 mg Oral

Indications

No indication recorded.